The development of an HIV vaccine has proven extraordinarily difficult. One of the reasons is that naïve precursor B cells that can give rise to mature B cells producing broadly neutralizing antibodies are exceedingly rare within the average human. Yet, despite their low frequency these B cell precursors can outcompete their B cell competitors under the right conditions.
